KKR and Hologic team up to create medical tech platform focused on lung cancer diagnostics
Private-equity firm KKR & Co. Inc. (KKR), Hologic Inc. (HOLX) are teaming up to create a new platform aimed at accelerating innovation in medical technology with an initial focus on lung cancer, the leading cause of cancer deaths. The platform will be named Maverix Medical and will be managed by Ajax Health under the stewardship of Duke Rohlen. KKR and Ajax will contribute the portfolio company Serpex Medical to the platform, as it's already working on technology to target lung tissue for biopsy or delivery of therapy. KKR's stock has gained 61% in the year to date, while the S&P 500 has gained 18.5%.
-Ciara Linnane
This content was created by MarketWatch, which is operated by Dow Jones & Co. MarketWatch is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
11-30-23 0616ET
Copyright (c) 2023 Dow Jones & Company, Inc.-
Six Sports Betting and iGaming Stocks Trading at a Discount
-
4 Predictions for Stocks and the Economy for the Second Half of 2024
-
What Broadening Rally? AI Stocks Dominate Again In Q2
-
After Earnings, Is Nike Stock a Buy, a Sell, or Fairly Valued?
-
Worst-Performing Stock ETFs of the Quarter
-
Top-Performing Stock ETFs of the Quarter
-
Q2 In Review and Q3 2024 Market Outlook
-
5 Stocks to Buy for 3Q 2024
-
Industrials: Sector Offers Investment Opportunities as Performance Lags Broader Market
-
Consumer Defensives: Even Amid Macro Pressures, Deals Permeate the Landscape
-
33 Undervalued Stocks
-
Utilities: Can the Stocks Keep the Rally Going?
-
Basic Materials: Following Index Decline, We See Many Long-Term Opportunities
-
Healthcare: Valuations Look Attractive In Most Industries
-
Financial Services: Amid Uncertainties, We See the Most Value In Banks and Credit Services
-
Consumer Cyclicals: Even With Anxiety Over Spending, We See Attractive Valuations